Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(15):1204-1205; doi:10.1093/jnci/92.15.1204
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Amber, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amber, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 15, 1204-1205, August 2, 2000
© 2000 Oxford University Press

NEWS

Pharmacoeconomic Analyses Make Way Into Oncology

Dave Amber

As drug prices soar and drug management budgets decrease, a central question for health care providers is how to make the most of less. And pharmaceutical companies, as well as managed care and government providers, are looking more and more to pharmacoeconomics—the use of economic analysis in health care and drug comparison—to help decide which drugs or treatment options they should pay for.

Although this kind of information is not required by law—the U.S. Food and Drug Administration is concerned with efficacy and with marketing . . . [Full Text of this Article]

Cost Analyses

Quality of Life

Developing Standards


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?